Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors.
Fumagillin is an active amebicide and anti-infective isolated from the fungus Aspergillus fumigatus. Since its characterization in 1951, fumagillin has been studied extensively for its anti-infective properties. Although fumagillin is not approved for systemic use in the USA, this compound has one of the highest efficacies for the treatment of microsporidial infections in HIV-positive patients. Fumagillin does exhibit some side effects that have deterred its acceptance as a viable treatment, but the current body of research on the synthesis of novel analogs of this molecule shows an exciting and promising revival of this drug as both an anti-infective and antiangiogenic agent.
Department of Dermatology, Emory University School of Medicine, Atlanta, GA 30322, USA. benjaminlefkove@hotmail.com
Benjamin
B
Lefkove
Baskaran
B
Govindarajan
Jack L
JL
Arbiser
D000626:Aminopeptidases / Q000037:antagonists & inhibitors / Q000737:chemistry; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D003510:Cyclohexanes / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D005231:Fatty Acids, Unsaturated / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000737:chemistry; D006801:Humans; D063208:Methionyl Aminopeptidases; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012717:Sesquiterpenes / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000890:Anti-Infective Agents; D003510:Cyclohexanes; D005231:Fatty Acids, Unsaturated; D006023:Glycoproteins; D012717:Sesquiterpenes; C026211:fumagillin; D000626:Aminopeptidases; C081311:METAP2 protein, human; D063208:Methionyl Aminopeptidases; D000077609:O-(Chloroacetylcarbamoyl)fumagillol